Clinical Trial Update: Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

View source ↗

Summary

A completed clinical trial evaluated additional risk minimisation measures for REBLOZYL among healthcare professionals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Myelodysplastic Syndromes

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes, Beta-thalassemia | Status: COMPLETED